Back to Peptipedia
MetabolismHuman research

Retatrutide

Retatrutide is a triple receptor agonist in clinical development and is not an approved medicine.

Peptipedia explains research and prescribing information. It does not replace medical advice and is not an invitation to use a substance.

Research areas

Source-based short profile

Evidence matrix

Molecular identity
Confirmed

Retatrutide (LY3437943) is a defined triple-receptor-agonist peptide from clinical studies. Research products without manufacturer specifications are not established as identical.

Human research
Moderate
Replication
Single research group
Clinical endpoints
Symptom- or function-related
Safety
Limited characterization
Approval
No documented approval

The dimensions are presented separately and are not combined into an overall score.

What the source shows

The peer-reviewed phase 2 study assessed weight changes over 48 weeks.

Research gaps

  • ·Full phase 3 publications, long-term safety and regulatory benefit–risk review remain outstanding.
  • ·Short profile: not a complete benefit–risk assessment. Unlisted contraindications and interactions are not adequately established in this profile; missing information does not establish safety.